# A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

> **NCT07477704** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 420 (estimated)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab

## Key facts

- **NCT ID:** NCT07477704
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2026-10-20
- **Final completion:** 2027-03-09
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477704, "A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07477704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*